Evidence map›Paper›PMID 41586841›Full record

ArticleApplied microbiology and biotechnology2026

An improved CRISPR-Cas9 protein-based method for knocking out insect Sf9 cell genes.

Miguel Graça, Nikolaus Virgolini, Ricardo Correia, Jose Escandell, António Roldão

Abstract read
In one paragraph

Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Miguel GraçaiBET, Instituto de Biologia Experimental E Tecnológica, Apartado 12, Oeiras, 2780-901, Portugal.
Nikolaus VirgoliniiBET, Instituto de Biologia Experimental E Tecnológica, Apartado 12, Oeiras, 2780-901, Portugal.
Ricardo CorreiaiBET, Instituto de Biologia Experimental E Tecnológica, Apartado 12, Oeiras, 2780-901, Portugal.
Jose EscandelliBET, Instituto de Biologia Experimental E Tecnológica, Apartado 12, Oeiras, 2780-901, Portugal.
António RoldãoiBET, Instituto de Biologia Experimental E Tecnológica, Apartado 12, Oeiras, 2780-901, Portugal. aroldao@ibet.pt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insect cells are one of the uprising expression systems in the biopharmaceutical industry to produce vaccines and gene therapy vectors, but cell line development has been limited by the lack of established genetic engineering tools and genomic characterization. CRISPR-Cas9 has arisen as a powerful tool for gene editing but has seen little application in insect cells. In this work, a gene editing pipeline for the delivery of a ribonucleoprotein (RNP) complex comprised of a guide RNA and the enzyme Cas9 to insect Sf9 cells was implemented and then applied to knockout caspase initiator Sf-Dronc, aiming at alleviating cell apoptosis during an infection process. The resulting engineered cell lines were characterized as per their phenotype and production of three different product modalities. Utilizing the established workflow, a knockout rate of 68% was achieved with the implemented protocol (vs. the 12% presumed efficiency of a previously reported system) when targeting the fdl gene. When applied to Sf-Dronc, mutants containing deletions in several alleles of the host genome were identified and confirmed by next-generation sequencing. Generated clones exhibited higher apoptosis resistance and delayed onset of cell viability drop following infection with baculovirus. While Sf-Dronc deletion was shown to have negligible impact on the production of rAAV and PfRipr5, production of iVLPS showed an > twofold increase over wild-type Sf9. Overall, this study showcases the successful implementation of an efficient CRISPR-Cas9 pipeline, further leveraging the usage of genetic engineering in insect Sf9 cells towards the development of enhanced cell hosts for biopharmaceutical production. KEY POINTS: • Implementation of an efficient CRISPR-Cas9 RNP complex delivery strategy to insect cells. • Establishment of the genome editing pipeline demonstrated through Sf-Dronc knockout, resulting in increased apoptosis resistance and delayed loss of viability upon baculovirus infection. • Sf-Dronc deletion led to over a twofold increase in the production of influenza VLPs compared to wild-type Sf9 cells.

Indexed as

CRISPR-Cas SystemsGene EditingGene Knockout TechniquesAnimalsApoptosisBaculoviridaeRNA, Guide, CRISPR-Cas SystemsSf9 CellsSpodopteraRNA, Guide, CRISPR-Cas SystemsAdvanced therapy medicinal productsApoptosisBaculovirus expression vector systemCell line developmentCRISPR-Cas9Spodoptera frugiperda

Identifiers

PMID41586841
PMCPMC12847097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.